These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3714560)

  • 1. [Use of lomustine, teniposide, procarbazine and prednisone (LTPP) in the treatment of terminal-state Hodgkin's disease].
    Robak T; Krykowski E; Olszańska-Skorek T; Urbańska-Ryś H; Dmochowska M; Chojnowski K
    Pol Tyg Lek; 1986 Feb; 41(7):199-202. PubMed ID: 3714560
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
    Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mopp chemotherapy in the treatment of stage IV Hodgkin's disease.
    Fiacchini M; Lauria F; Mazza P; Cantore M; Gherlinzoni F; Tura S
    Haematologica; 1985; 70(2):148-54. PubMed ID: 3924778
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of malignant lymphoma: 12 years' experience with 109 patients. 1). Treatment of Hodgkin's disease].
    Furukawa Y; Takagi S; Tsuboyama A; Akashi M; Komatsu N; Takeda K; Muroi K; Ohsaka A; Ohta M; Suda K
    Rinsho Ketsueki; 1987 Sep; 28(9):1539-43. PubMed ID: 3437515
    [No Abstract]   [Full Text] [Related]  

  • 7. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
    Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
    Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of Hodgkin's disease including the staging laparotomy].
    Yosida T; Nakanisi J; Kobayasi S; Ohtake S; Ito K; Nakamura S; Hattori K; Saito Y; Tanimoto K
    Rinsho Ketsueki; 1984 Jun; 25(6):827-34. PubMed ID: 6548266
    [No Abstract]   [Full Text] [Related]  

  • 11. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of Hodgkin's disease: patients who fail to remit or who relapse after combination chemotherapy.
    Sutcliffe SB; Economopoulos T; Wrigley PF; Stansfeld AG; Malpas JS
    Clin Oncol; 1980 Dec; 6(4):329-36. PubMed ID: 6161731
    [No Abstract]   [Full Text] [Related]  

  • 15. [CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
    Sampi K; Honda T; Hattori M
    Rinsho Ketsueki; 1984 Feb; 25(2):164-8. PubMed ID: 6547984
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term follow-up of two chemotherapy protocols in Hodgkin's disease.
    Pavlovsky S; Morgenfeld M; Somoza N; Magnasco J; Sackmann Muriel F; Cavagnaro F; Suárez A; Barros CA; Saslavsky J; Garay G; Palau M; Besuschio SC
    Medicina (B Aires); 1981; 41 Suppl():15-21. PubMed ID: 6896551
    [No Abstract]   [Full Text] [Related]  

  • 17. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hodgkin's disease in children; treatment results with or without radiotherapy].
    Behrendt H
    Ned Tijdschr Geneeskd; 1986 May; 130(19):865-8. PubMed ID: 3754935
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of the efficacy of radiotherapy in the combined treatment of generalized Hodgkin's disease in children].
    Tsyplenkov VG; Sviridova AV
    Med Radiol (Mosk); 1984 Oct; 29(10):34-7. PubMed ID: 6548787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.